ANTHEM BIOSCIENCES Financial Statement Analysis
|
||
|
The Revenues of ANTHEM BIOSCIENCES have increased by 15.17% YoY .
The Earnings Per Share (EPS) of ANTHEM BIOSCIENCES has increased by 30.61 % YoY. |
||
ANTHEM BIOSCIENCES Last 5 Annual Financial Results
[BOM: 544449|NSE : ANTHEM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,124 Cr | ₹1,845 Cr | ₹1,419 Cr | ₹1,057 Cr | ₹1,231 Cr |
| Expenses | ₹1,290 Cr | ₹1,174 Cr | ₹914 Cr | ₹634 Cr | ₹664 Cr |
| Operating Profit (Excl OI) | ₹834 Cr | ₹671 Cr | ₹505 Cr | ₹423 Cr | ₹567 Cr |
| Other Income | ₹156 Cr | ₹86 Cr | ₹64 Cr | ₹85 Cr | ₹49 Cr |
| Interest | ₹7.06 Cr | ₹11 Cr | ₹9.66 Cr | ₹8.72 Cr | ₹12 Cr |
| Depreciation | ₹134 Cr | ₹89 Cr | ₹82 Cr | ₹64 Cr | ₹58 Cr |
| Profit Before Tax | ₹824 Cr | ₹657 Cr | ₹477 Cr | ₹497 Cr | ₹546 Cr |
| Profit After Tax | ₹592 Cr | ₹451 Cr | ₹367 Cr | ₹385 Cr | ₹406 Cr |
| Consolidated Net Profit | ₹592 Cr | ₹451 Cr | ₹367 Cr | ₹385 Cr | ₹406 Cr |
| Earnings Per Share (Rs) | ₹10.54 | ₹8.07 | ₹6.57 | ₹6.75 | ₹462.10 |
| PAT Margin (%) | 27.11 | 24.38 | 25.88 | 36.44 | 32.94 |
| ROE(%) | 21.98 | 20.99 | 20.04 | 24.89 | 39.44 |
| ROCE(%) | 29.62 | 28.55 | 24.21 | 31.08 | 50.94 |
| Total Debt/Equity(x) | 0.02 | 0.05 | 0.12 | 0.07 | 0.03 |
Key Financials |
||
| Market Cap | : | ₹ 53,991.2 Cr |
| Revenue (TTM) | : | ₹ 2,046.4 Cr |
| Net Profit(TTM) | : | ₹ 614.0 Cr |
| EPS (TTM) | : | ₹ 10.9 |
| P/E (TTM) | : | 87.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ANTHEM BIOSCIENCES | 8.1% | 11.3% | 33.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 7.3% | 8.4% | 13.1% |
| DIVIS LABORATORIES | 15.3% | 24.1% | 63% |
| TORRENT PHARMACEUTICALS | 1% | 2.5% | 33.4% |
| CIPLA | 0.4% | 7.9% | -6.2% |
| DR REDDYS LABORATORIES | 1% | 15.9% | 14% |
| MANKIND PHARMA | 5.1% | 12.3% | 8.8% |
| LUPIN | -0.2% | 2.7% | -0.2% |
| ZYDUS LIFESCIENCES | 1.9% | 8.8% | 23.4% |
ANTHEM BIOSCIENCES Revenues
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 15.17 % |
| 5 Yr CAGR | 14.61 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,124 Cr | 15.17 | |
| Mar2025 | ₹1,845 Cr | 29.96 | |
| Mar2024 | ₹1,419 Cr | 34.29 | |
| Mar2023 | ₹1,057 Cr | -14.16 | |
| Mar2022 | ₹1,231 Cr | - | |
ANTHEM BIOSCIENCES Operating Profit
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 24.28 % |
| 5 Yr CAGR | 10.12 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹834 Cr | 24.28 | |
| Mar2025 | ₹671 Cr | 32.85 | |
| Mar2024 | ₹505 Cr | 19.45 | |
| Mar2023 | ₹423 Cr | -25.43 | |
| Mar2022 | ₹567 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 7.92 % |
| 5 Yr CAGR | -3.91 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 39.26% | 7.92 | |
| Mar2025 | 36.38% | 2.22 | |
| Mar2024 | 35.59% | -11.05 | |
| Mar2023 | 40.01% | -13.14 | |
| Mar2022 | 46.06% | - | |
ANTHEM BIOSCIENCES Profit After Tax
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 31.14 % |
| 5 Yr CAGR | 9.91 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹592 Cr | 31.14 | |
| Mar2025 | ₹451 Cr | 22.86 | |
| Mar2024 | ₹367 Cr | -4.64 | |
| Mar2023 | ₹385 Cr | -5.02 | |
| Mar2022 | ₹406 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 11.20 % |
| 5 Yr CAGR | -4.75 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 27.11 % | 11.20 | |
| Mar2025 | 24.38 % | -5.80 | |
| Mar2024 | 25.88 % | -28.98 | |
| Mar2023 | 36.44 % | 10.63 | |
| Mar2022 | 32.94 % | - | |
ANTHEM BIOSCIENCES Earnings Per Share (EPS)
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 30.61 % |
| 5 Yr CAGR | -61.14 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹11 | 30.61 | |
| Mar2025 | ₹8.07 | 22.83 | |
| Mar2024 | ₹6.57 | -2.67 | |
| Mar2023 | ₹6.75 | -98.54 | |
| Mar2022 | ₹462 | - | |
ANTHEM BIOSCIENCES Return on Capital Employed (ROCE)
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 3.75 % |
| 5 Yr CAGR | -12.68 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 29.62% | 3.75 | |
| Mar2025 | 28.55% | 17.93 | |
| Mar2024 | 24.21% | -22.10 | |
| Mar2023 | 31.08% | -38.99 | |
| Mar2022 | 50.94% | - | |
ANTHEM BIOSCIENCES Share Price vs Sensex
| Current Share Price | : | ₹957.8 |
| Current MarketCap | : | ₹ 53,991.2 Cr |
| Updated EOD on | : | Nov 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANTHEM BIOSCIENCES | 8.1% |
11.3% |
33.7% |
| SENSEX | 5.9% |
13% |
-1.9% |
ANTHEM BIOSCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 500 | 4.5% | 8.8% | 0.2% |
| BSE 1000 | 4.3% | 8.1% | 0.6% |
| BSE SELECT IPO INDEX | 4.1% | 5.4% | -2.5% |
| BSE HEALTHCARE | 3.7% | 8.5% | 18.1% |
| BSE 400 MIDSMALLCAP INDEX | 3.1% | 3.6% | 1.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | 4.4% | 8.8% | 0.4% |
| NIFTY TOTAL MARKET | 4.4% | 8.4% | 0.8% |
| NIFTY LARGEMIDCAP 250 | 4.3% | 8% | 1% |
| NIFTY INDIA MANUFACTURING | 3.9% | 8.4% | 6.5% |
| NIFTY500 HEALTHCARE INDEX | 3.8% | 9.4% | 18.4% |
You may also like the below Video Courses
FAQ about ANTHEM BIOSCIENCES Financials
How the annual revenues of ANTHEM BIOSCIENCES have changed ?
The Revenues of ANTHEM BIOSCIENCES have increased by 15.17% YoY .
How the Earnings per Share (EPS) of ANTHEM BIOSCIENCES have changed?
The Earnings Per Share (EPS) of ANTHEM BIOSCIENCES has increased by 30.61 % YoY .
Check out Intrinsic Value of Peers of ANTHEM BIOSCIENCES
Compare Stock Analytics of Peers of ANTHEM BIOSCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
